TY - JOUR T1 - Statistical Analysis Plan for the Helmet Non-Invasive Ventilation for COVID-19 Patients (Helmet-COVID) Randomized Controlled Trial JF - medRxiv DO - 10.1101/2021.07.26.21260421 SP - 2021.07.26.21260421 AU - Yaseen Arabi AU - Haytham Tlayjeh AU - Sara Aldekhyl AU - Hasan Al-Dorzi AU - Sheryl Ann Abdukahil AU - Jesna Jose AU - Mohammad Khulaif Al Harbi AU - Husain Al Haji AU - Mohammed Al Mutairi AU - Omar Al Zumai AU - Eman Al Qasim AU - Wedyan Al Wehaibi AU - Saad Al Qahtani AU - Mohammed Alshahrani AU - Talal Albrahim AU - Ahmed Mady AU - Ali Al Bshabshe AU - Zohair Al Aseri AU - Zainab Al Duhailib AU - Ayman Kharaba AU - Rakan Alqahtani AU - Haifa Algethamy AU - Omar Alfaris AU - Omar Alnafel AU - Abdulrahman A Al-Fares Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/30/2021.07.26.21260421.abstract N2 - Background and objective Noninvasive respiratory support is frequently needed for patients with acute hypoxemic respiratory failure due to coronavirus disease 19 (COVID-19). Helmet noninvasive ventilation having multiple advantages over other support modalities but data about effectiveness are limited.Methods In this multicenter randomized trial of helmet non-invasive ventilation for COVID-19 patients (Helmet-COVID), 320 adult ICU patients with suspected or confirmed COVID-19 and acute hypoxemic respiratory failure (with a ratio of arterial oxygen partial pressure to fraction (percent) of inspired oxygen (PaO2/FiO2) <200 despite supplemental oxygen with a partial/non-rebreathing mask at a flow rate >10 L/min or above) will be randomized to helmet-noninvasive ventilation with usual care or usual care alone. The primary outcome is death from any cause within 28 days after randomization. The trial has 80% power to detect a 15% absolute risk reduction from 40% to 25%.Conclusion Consistent with international guidelines, we developed a detailed plan to guide the analysis of the Helmet-COVID trial. This plan specifies the statistical methods for the evaluation of primary and secondary outcomes to facilitate unbiased analyses of clinical data.Trial registration Clinicaltrials.gov: NCT04477668 (registered on July 20, 2020)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicaltrials.gov: NCT04477668Funding StatementThe study is funded by King Abdullah International Medical Research Center (RC 20/306/R). The study sponsor does not have any role in the study design, collection, management, analysis, and interpretation of data as well as the writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Institutional Review Boards of King Abdulaziz Medical City- Riyadh; Aseer Central Hospital-Abha; King Fahad Hospital-Madinah; King Abdulaziz University Hospital-Jeddah; King Faisal Specialist Hospital and Research Center- Riyadh; King Fahad Hospital of the University- Dammam; King Khalid University Hospital-Riyadh; King Salman Specialist Hospital-Hail; King Saud Medical City-RiyadhAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOnce all planned analyses have been completed and published or presented, data will be shared upon reasonable request from the Chief Investigator.CIConfidence IntervalHRHazard RatioICUIntensive Care UnitIQRInterquartile RangeLOSLength of stayRT-PCRReverse Transcription–Polymerase Chain ReactionRCTRandomized Controlled TrialRRRelative RiskRRRRelative Risk ReductionSAPStatistical Analysis Plan ER -